Industrial platform

Orano Med has developed a patented chemical process allowing production of 212Pb on a large scale and at a reasonable cost

Large-scale production of 212Pb

Development of TAT has long been hindered by a lack of supply of alpha emitting radioisotopes meeting three important criteria: purity meeting radiopharmaceutical standards, reliable production capacity sufficient to meet global needs, and economic competitiveness.

With a unique and proprietary source of raw material (Thorium 232), Orano Med has developed a patented chemical process allowing production of 212Pb on a large scale and at a reasonable cost

Orano Med laboratory, Texas (United States) © Orano Med - HERNDON JIM

Facilities that are unique in the world


DDPU (Domestic Distribution and Purification Unit) laboratory, located in Plano, Texas (United States) © Orano Med - HERNDON JIM
macrocyclics
In order to be able to produce and distribute 212Pb-conjugated drugs, Orano Med has equipped itself with facilities which are unique worldwide:
  • In France at Bessines-sur-Gartempe, the Laboratoire Maurice Tubiana (LMT) produces the precursors of 212Pb (Radium 228 and Thorium 228) for the manufacturing of doses of 212Pb for preclinical research and clinical trials;

  • In the USA at Plano in Texas, the Domestic Distribution & Purification Unit (DDPU) produces 212Pb for North America and drugs for clinical trials in progress in accordance with GMP standards;

  • In the USA at Brownsburg in Indiana, the first Alpha Therapy Laboratory (ATLab) is currently under construction. As of 2024, it will commence the large-scale production of vectorized internal radiotherapy treatments and their distribution in North America. The construction of other ATLabs will be launched shortly to cover global needs.

  • In 2011, Orano Med also acquired Macrocyclics which has globally-recognized expertise in the production and development of chelating agents for nuclear medicine.
By clicking “I accept Cookies”, you agree with the cookies use to enhance site navigation, analyze site usage and compile statistics. To get more information, please read our Cookies Policy in the Legal Notice